6,843 Shares in Amgen Inc. $AMGN Purchased by 111 Capital

111 Capital acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,843 shares of the medical research company’s stock, valued at approximately $1,931,000.

A number of other institutional investors also recently modified their holdings of AMGN. Elo Mutual Pension Insurance Co increased its holdings in shares of Amgen by 2.3% in the third quarter. Elo Mutual Pension Insurance Co now owns 62,898 shares of the medical research company’s stock valued at $17,750,000 after purchasing an additional 1,417 shares in the last quarter. Cobblestone Capital Advisors LLC NY lifted its holdings in Amgen by 2.1% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 1,731 shares of the medical research company’s stock worth $488,000 after buying an additional 35 shares in the last quarter. Fisher Asset Management LLC boosted its position in Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after buying an additional 375,463 shares during the last quarter. New Age Alpha Advisors LLC increased its stake in shares of Amgen by 3.0% in the 3rd quarter. New Age Alpha Advisors LLC now owns 41,651 shares of the medical research company’s stock valued at $11,754,000 after buying an additional 1,211 shares during the period. Finally, Holderness Investments Co. increased its stake in shares of Amgen by 2.2% in the 3rd quarter. Holderness Investments Co. now owns 7,786 shares of the medical research company’s stock valued at $2,197,000 after buying an additional 169 shares during the period. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on AMGN shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Truist Financial boosted their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. BMO Capital Markets upped their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Rothschild & Co Redburn lifted their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, Scotiabank began coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Stock Performance

NASDAQ:AMGN opened at $388.16 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a 50 day simple moving average of $348.89 and a 200 day simple moving average of $319.93. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $390.14. The stock has a market cap of $209.25 billion, a P/E ratio of 27.28, a PEG ratio of 3.85 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.